2 Most Recently Initiated Coverage with Target @$16
01-19-2007 09:08:21 AM
1.) BB&T CAPITAL
TARGET: $16.00
BB&T CAPITAL initiates coverage on Medifast (AMEX: MED)
with a Buy rating and $16 price target.
Medifast is the leading easy-to-use, clinically proven meal replacement program. Medifast has been recommended by 15,000 physicians and used by over one million customers. Its programs have been proven effective through studies by researchers from major university teaching hospitals.
http://www.streetinsider.com/New+Coverage/BB&T+Capital+Starts+Medifast+(MED)+at+Buy/1509308.html
January 21, 2007 9:28:58 AM ET
2) eResearch
TARGET: 16.00
Medifast initiated with "buy"
January 21, 2007 9:28:58 AM ET
eResearch
NEW YORK, January 22 (newratings.com) - Analyst Laura Richardson of eResearch initiates coverage of Medifast Inc (MDF.ETR) with a "buy" rating. The 12-month target price is set to $16.
In a research note published on January 19, the analyst mentions that the company is well positioned to benefit going forward from weight-related concerns and is poised to capitalize on this trend through an increase in its ad spending. Medifast faces an opportunity to generate over $700 million in revenues in the forthcoming five-to-ten years, the analyst says. The company is expected to achieve 38% and 30% earnings growth this year and in the long-term, respectively, eResearch adds.
http://www.newratings.com/analyst_news/article_1460039.html
01-19-2007 09:08:21 AM
1.) BB&T CAPITAL
TARGET: $16.00
BB&T CAPITAL initiates coverage on Medifast (AMEX: MED)
with a Buy rating and $16 price target.
Medifast is the leading easy-to-use, clinically proven meal replacement program. Medifast has been recommended by 15,000 physicians and used by over one million customers. Its programs have been proven effective through studies by researchers from major university teaching hospitals.
http://www.streetinsider.com/New+Coverage/BB&T+Capital+Starts+Medifast+(MED)+at+Buy/1509308.html
January 21, 2007 9:28:58 AM ET
2) eResearch
TARGET: 16.00
Medifast initiated with "buy"
January 21, 2007 9:28:58 AM ET
eResearch
NEW YORK, January 22 (newratings.com) - Analyst Laura Richardson of eResearch initiates coverage of Medifast Inc (MDF.ETR) with a "buy" rating. The 12-month target price is set to $16.
In a research note published on January 19, the analyst mentions that the company is well positioned to benefit going forward from weight-related concerns and is poised to capitalize on this trend through an increase in its ad spending. Medifast faces an opportunity to generate over $700 million in revenues in the forthcoming five-to-ten years, the analyst says. The company is expected to achieve 38% and 30% earnings growth this year and in the long-term, respectively, eResearch adds.
http://www.newratings.com/analyst_news/article_1460039.html
Recent MED News
- Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026 • Business Wire • 04/20/2026 08:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/06/2026 08:16:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 08:08:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 09:52:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 09:51:17 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 03/20/2026 04:55:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 12:35:54 PM
- Medifast Announces Cooperation Agreement with Steamboat Capital • Business Wire • 03/20/2026 12:30:00 PM
- Scientific Evidence Demonstrates OPTAVIA®’s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients • Business Wire • 02/20/2026 01:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/17/2026 09:54:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 09:44:44 PM
- Medifast Announces Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 02/17/2026 09:05:00 PM
- Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025 • Business Wire • 02/03/2026 09:05:00 PM
- The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings • PR Newswire (Canada) • 01/19/2026 05:10:00 PM
- The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings • PR Newswire (US) • 01/19/2026 05:10:00 PM
- People Magazine Spotlights Tiffany Howard’s Metabolic Health Journey with OPTAVIA® • Business Wire • 01/16/2026 01:30:00 PM
- OPTAVIA® Premieres Second Docuseries Episode “Health by Design: Spain” Exploring Metabolic Health and Longevity • Business Wire • 01/15/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 02:02:04 PM
- Medifast Announces Planned Leadership Transition • Business Wire • 01/05/2026 02:00:00 PM
- OPTAVIA Survey Reveals 80% of Americans Lack Understanding of Metabolic Health Despite Its Major Impact to Overall Health and Wellbeing • Business Wire • 12/09/2025 01:30:00 PM
- Medifast Scientific & Clinical Affairs Team Showcases New Research in Metabolic Health at ObesityWeek Conference • Business Wire • 11/13/2025 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/03/2025 09:51:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 09:15:23 PM
